Roche's Q2 2026 earnings call, held on July 23, 2026, was dominated by positive Phase III data for divarasib in KRAS G12C-positive NSCLC, prompting management to begin reassessing the asset's commercial potential. Investors also focused on Roche's advancing obesity pipeline, and the addition of a BTK degrader through a newly closed partnership with Nurix Therapeutics
In terms of financial performance, over the six-month period Roche's pharmaceutical sales achieved growth of 6% year-on-year at constant exchange rates to CHF 23.62 billion (USD 28.8 billion), with core operating profit rising 10% and core earnings per share up 9%.
Divarasib: Peak Sales Guidance Under Revision After Phase III Superiority Data
Roche's earnings call included discussion of the positive outcome of the Krascendo 1 Phase III trial of divarasib in second-line-plus KRAS G12C-positive NSCLC. The study was designed as a head-to-head comparison against currently approved KRAS G12C inhibitors — sotorasib and adagrasib — and management said the results demonstrated superiority on both progression-free survival (PFS) and overall survival (OS), with OS statistical significance reached at an interim analysis. Teresa Graham, Chief Executive Officer of Roche Pharmaceuticals, described the safety profile as consistent with prior data and said the data would be submitted to health authorities and presented at an upcoming medical congress.
The existing peak sales estimate of CHF 1 billion to CHF 2 billion was explicitly flagged for upward revision. Graham told analysts that Roche is currently consulting with thought leaders and reevaluating the clinical trial program, with a formal update expected at Pharma Day on September 28. CEO Thomas Schinecker added that the upside case for divarasib extends beyond NSCLC, noting that RAS mutations are among the most prevalent oncogenic drivers across multiple tumor types.
Separately, Phase II Krascendo 170 data presented at ASCO showed that the combination of divarasib with pembrolizumab produced strong efficacy results across PD-L1-positive and -negative cohorts in first-line NSCLC, which management said supported the ongoing Phase III Krascendo 2 trial in the same setting. Roche also disclosed a broader RAS-targeted pipeline including G12D-specific and pan-mutation assets, positioning the franchise for potential use across multiple mutation classes. When analysts asked how divarasib should be evaluated against emerging pan-RAS agents, Graham acknowledged a role for pan-RAS inhibitors but said the high prevalence and specificity of the G12C mutation favored a targeted approach for patients harboring that alteration.
Giredestrant: November PDUFA Approaches Amid Physician Adoption Questions
The PDUFA date for giredestrant in adjuvant estrogen receptor-positive (ER-positive), HER2-negative early breast cancer was set for November 30 under the lidERA trial program, with a second PDUFA for the evERA metastatic program set for December 18. Management said no advisory committee meeting has been indicated to date following priority review.
Analysts pressed on the pace of physician adoption. Graham acknowledged that some KOLs at ASCO raised questions about the absence of longer-term PFS and OS data versus CDK4/6 inhibitors, but said Roche's conversations with potential prescribers indicated broad enthusiasm, driven primarily by tolerability: approximately 50% of patients currently on CDK4/6-based therapy cannot sustain treatment, she said, creating a population of patients either waiting for an alternative or having already discontinued. Management said switch data for patients currently on CDK4/6 therapy is being generated but is not yet available, and that the EU filing is being deliberately delayed to allow the data package to mature.
Schinecker added that giredestrant holds both a potency advantage and a superior safety profile relative to another approved selective estrogen receptor degrader (SERD), without naming the comparator. Analysts from Deutsche Bank and BNP Paribas raised pricing concerns, noting that SERDs have launched above USD 300,000 annually in the metastatic setting, which could constrain broad adjuvant adoption. Graham declined to provide pricing guidance prior to approval but said Roche has historically maintained tighter US-to-ex-US price corridors than some competitors and would price based on clinical value, payer capacity, and the need to sustain R&D investment.
BTK Degrader: Nurix Partnership Adds Targeted Protein Degradation to Hematology and Immunology
Roche closed its collaboration with Nurix Therapeutics to co-develop bexobrutideg (bexdeg), a BTK degrader, during Q2. Management positioned the molecule as differentiated from existing BTK inhibitors — including ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib — on the basis that full protein degradation eliminates all BTK functions, including those that may persist with inhibitor-based approaches, and that degradation can overcome resistance mutations associated with BTK inhibitor failure. Management also cited blood-brain barrier penetration as a distinguishing characteristic.
A Phase III trial in first-line-plus chronic lymphocytic leukemia (CLL), running head-to-head against pirtobrutinib, has already been initiated. A basket combination trial in CLL is also planned. Graham said Phase II trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) are in planning, citing the validated role of BTK across both hematological malignancies and autoimmune conditions. When asked by Goldman Sachs analyst James Quigley whether the differentiation would manifest primarily in efficacy, safety, tolerability, or combinability, Graham said all four, while acknowledging the asset is early-stage for Roche and that more detail would be provided at Pharma Day.
NXT007 / Zemocimig: Hemophilia Franchise Succession Planning Underway
NXT007 (zemocimig), described by Schinecker as approximately 30 times more potent than emicizumab (Hemlibra), has enrolled its first patient in a Phase III head-to-head trial versus Hemlibra. Bruno Eschli, Head of Investor Relations, said data are expected around year-end 2027 or early 2028. Management said the 360-patient trial design is statistically powered based on known Hemlibra performance and the assumed potency of NXT007.
When Deutsche Bank analyst Emmanuel Papadakis asked whether the trial was designed for superiority or non-inferiority, Graham declined to specify the primary endpoint structure but said the program is intended to demonstrate meaningful patient benefit beyond what Hemlibra currently provides, citing durability and convenience. She characterized antidrug antibodies (ADAs) observed in the Phase I/II study as not clinically meaningful — noting no impact on pharmacokinetics, efficacy, or safety and no cross-reactions — while confirming ongoing monitoring. The Hemlibra full-year growth outlook was revised upward to mid-single-digit from low-single-digit, though management flagged anticipated competitive headwinds in H2 2026 from upcoming competitor launches.